Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. - Wikidata - wikimedia - TriplyDB

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q37401654

about

Kinase inhibitors for advanced medullary thyroid carcinoma.2012 European thyroid association guidelines for metastatic medullary thyroid cancer.Treatment of advanced medullary thyroid cancer.

P2860

Q35895485-73D62A45-A045-462C-ADBD-7FE57B615A12 Q37290840-6E7BA3D1-1AD5-403A-A745-958582947C2C Q41043040-0E33B1BE-BA49-40B0-8B77-61CE8BDBC77F

P2860

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q37401654

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@en

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@nl

type

label

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@en

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@nl

prefLabel

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@en

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

@nl

P1433

Q37401654-E753A281-1643-407D-AE13-039849D7E560

P1476

Q37401654-D5F5514D-5BE9-40DC-AE82-97CD3B0E5867

P2093

Q37401654-07F46854-2A4C-4D36-BEE3-4A7573CF9FC0

Q37401654-29E34920-7C9E-4255-8E31-F2DF36238FA6

Q37401654-7272C86E-3E8C-4EBB-B42B-2C54DB116E52

Q37401654-F49DFD54-96CF-4B99-B195-A140BFFAB5A3

P2860

Q37401654-091D6FE4-3AF2-4BED-A736-8423148F9B64

Q37401654-3A4F1040-6257-4970-B10D-41DEB020D497

Q37401654-3F4CE326-F1F6-432C-88B1-2E35EA148078

Q37401654-40FCE767-1F3D-435E-875A-AEF00BC64047

Q37401654-4EEB88C4-A50C-41E6-B4DD-1421E27B3175

Q37401654-5088B140-5F29-4D9C-AFE8-BECEB3EBACDD

Q37401654-5FACAA9D-A95E-48FA-AB7A-9DA567421BDF

Q37401654-6078D57E-88AF-4777-86AF-42E984493787

Q37401654-65118564-E819-4265-B9DD-F0C77DEAED99

Q37401654-6B6CFFA1-650C-4912-81B7-60B36FC8C49E

P304

Q37401654-1BCE8C1B-50F7-4AF2-B22E-009A4C881C6D

P31

Q37401654-07F6048E-B1EE-4A2A-98F7-8D40DE9B32C2

P356

Q37401654-98F71D9F-E36A-437A-9D80-FB9C5F16548C

P433

Q37401654-6A6DAB05-1645-4B88-8EDF-CB1A26825537

P478

Q37401654-C27933DA-3F45-48D8-84F1-73F7CE5791D6

P577

Q37401654-186BA78B-DB17-455F-8204-3D74A0105E7D

P698

Q37401654-F478382B-FF52-4548-B5D6-47988F2BAB37

P932

Q37401654-598676D4-0527-4ED8-B039-433EAC6F19CD

P356

P1433

Current Oncology

P1476

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

@en

P2093

D M Goldenberg

http://www.w3.org/2001/XMLSchema#string

F Kraeber-Bodéré

http://www.w3.org/2001/XMLSchema#string

J Barbet

http://www.w3.org/2001/XMLSchema#string

J F Chatal

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.

Pretargeting with the affinity enhancement system for radioimmunotherapy.

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

New therapeutic approaches to treat medullary thyroid carcinoma.

Chemoembolization for liver metastases from medullary thyroid carcinoma.

The Ki67 index a prognostic marker in medullary thyroid carcinoma.

Long-term outcome of reoperations for medullary thyroid carcinoma.

Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.

P304

3-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.V16I5.464

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19862356

http://www.w3.org/2001/XMLSchema#string

P932

2768511

http://www.w3.org/2001/XMLSchema#string